Viral Vector CDMO Services

Selecting a viral vector CDMO is one of the most consequential decisions your program will make, and the cost of choosing a partner without the right experience, capacity, or regulatory depth can be measured in years of delay. With more than 20 years of CGMP manufacturing experience, over 200 viral vector products produced, and 1,200+ GMP lots delivered, Thermo Fisher's Viral Vector Services (VVS) brings a track record that few organizations can match, including 3 commercially approved products.

Your program needs a partner that can grow with you. VVS operates across 85,000+ square feet of manufacturing space with 28 drug substance suites, 4 drug product suites, and 2 late-phase and commercial manufacturing facilities across the US and Europe. Whether your vector is AAV, lentiviral, adenoviral, herpesviral, retroviral, or something novel, you get access to 10 manufacturing modalities and expertise across 12+ AAV serotypes.

Beyond manufacturing, VVS provides end-to-end support: process development, analytical testing, tech transfer, fill-finish, and regulatory services covering CMC dossier preparation, health authority meeting support, and compliance across US, EU, and Canadian jurisdictions. Three service pathways, from the Rapid Development Framework to client tech transfer programs, let you match the approach to your timeline and budget.

Download the brochure now to understand exactly how VVS can support your viral vector program from IND-enabling studies through commercial launch.